Cabaletta Bio, Inc.
CABANASDAQHealthcare● Active
$3.20
$-0.05(-1.54%)
Market Cap$521775347
P/E Ratio—
52W High$4.23
52W Low$1.26
Cabaletta Bio, Inc. (CABA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CABA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.39
Est. -$0.41 · +4.9%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
CABA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.37 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$0.41 | -$0.39 | +4.9% | — | $0.00B | — |
| ▲ Q1 FY2026 | Mar 23, 2026 | -$0.45 | -$0.40 | +11.1% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 10, 2025 | -$0.49 | -$0.44 | +10.2% | — | — | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.71 | -$0.73 | -2.8% | — | $0.00B | — |
| ▼ Q2 FY2025 | May 15, 2025 | -$0.67 | -$0.71 | -6.0% | — | — | — |
| — Q1 FY2025 | Mar 31, 2025 | -$0.65 | -$0.65 | +0.0% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.59 | -$0.62 | -5.1% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.37
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
-$0.39
EPS Est.
-$0.41
EPS Surpr.
+4.9%
Revenue
—
Q1 FY2026
Mar 23, 2026Beat
EPS Actual
-$0.40
EPS Est.
-$0.45
EPS Surpr.
+11.1%
Revenue
—
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
-$0.44
EPS Est.
-$0.49
EPS Surpr.
+10.2%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.73
EPS Est.
-$0.71
EPS Surpr.
-2.8%
Revenue
—
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$0.71
EPS Est.
-$0.67
EPS Surpr.
-6.0%
Revenue
—
Q1 FY2025
Mar 31, 2025
EPS Actual
-$0.65
EPS Est.
-$0.65
EPS Surpr.
+0.0%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.62
EPS Est.
-$0.59
EPS Surpr.
-5.1%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q3 FY2027 | $-0.31 | $-0.31 | $-0.31 | 1 |
| Q2 FY2027 | $-0.31 | $-0.31 | $-0.31 | 1 |
| Q1 FY2027 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Q4 FY2026 | $-0.33 | $-0.33 | $-0.33 | 1 |
| Q3 FY2026 | $-0.38 | $-0.33 | $-0.27 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +4.9% | $3.59 | $3.61 | +0.56% |
| ▲ Q1 FY2026 | Mar 23, 2026 | +11.1% | $2.94 | $2.82 | -4.08% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +10.2% | $2.55 | $2.43 | -4.71% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -2.8% | $1.45 | $1.45 | +0.00% |
| ▼ Q2 FY2025 | May 15, 2025 | -6.0% | $1.30 | $1.81 | +39.23% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +0.0% | $1.55 | $1.39 | -10.32% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -5.1% | $4.01 | $3.78 | -5.74% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -1.8% | $6.11 | $4.01 | -34.37% |
Q2 FY2026+0.56%
Report Date
May 14, 2026
EPS Beat/Miss
+4.9%
Price Before
$3.59
Price After
$3.61
Q1 FY2026-4.08%
Report Date
Mar 23, 2026
EPS Beat/Miss
+11.1%
Price Before
$2.94
Price After
$2.82
Q4 FY2025-4.71%
Report Date
Nov 10, 2025
EPS Beat/Miss
+10.2%
Price Before
$2.55
Price After
$2.43
Q3 FY2025+0.00%
Report Date
Aug 7, 2025
EPS Beat/Miss
-2.8%
Price Before
$1.45
Price After
$1.45
Q2 FY2025+39.23%
Report Date
May 15, 2025
EPS Beat/Miss
-6.0%
Price Before
$1.30
Price After
$1.81
Q1 FY2025-10.32%
Report Date
Mar 31, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.55
Price After
$1.39
Q4 FY2024-5.74%
Report Date
Nov 14, 2024
EPS Beat/Miss
-5.1%
Price Before
$4.01
Price After
$3.78
Q3 FY2024-34.37%
Report Date
Aug 8, 2024
EPS Beat/Miss
-1.8%
Price Before
$6.11
Price After
$4.01
Avg Beat Reaction-4.64%
Avg Miss Reaction-0.22%
Beat Rate4 / 8 quarters
Largest Move+39.23% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CABA ends December
Cabaletta Bio, Inc. (CABA) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.39 — beating the analyst consensus of $-0.41 by +4.9%. CABA has beaten EPS estimates for 3 consecutive quarters. The next CABA earnings date is expected around September 1, 2026.
Each quarter, investors track CABA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CABA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CABA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CABA earnings · 5 questionsCabaletta Bio, Inc.'s next earnings report is expected around September 1, 2026. CABA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CABA historically reports after market close (AMC).
CABA earnings datewhen is CABA earningsCABA next earnings datewhen does CABA report earningsCABA earnings calendar
▸ Source: FMP · Cabaletta Bio, Inc. SEC filings · US GAAP · Cabaletta Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026